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Abstract
Background: Breathlessness in advanced disease causes significant distress to patients and carers and presents
management challenges to health care professionals. The Breathlessness Intervention Service (BIS) seeks to improve
the care of breathless patients with advanced disease (regardless of cause) through the use of evidence-based
practice and working with other healthcare providers. BIS delivers a complex intervention (of non-pharmacological
and pharmacological treatments) via a multi-professional team. BIS is being continuously developed and its impact
evaluated using the MRC’s framework for complex interventions (PreClinical, Phase I and Phase II completed). This
paper presents the protocol for Phase III.
Methods/Design: Phase III comprises a pragmatic, fast-track, single-blind randomised controlled trial of BIS versus
standard care. Due to differing disease trajectories, the service uses two broad service models: one for patients
with malignant disease (intervention delivered over two weeks) and one for patients with non-malignant disease
(intervention delivered over four weeks). The Phase III trial therefore consists of two sub-protocols: one for patients
with malignant conditions (four week protocol) and one for patients with non-malignant conditions (eight week
protocol). Mixed method interviews are conducted with patients and their lay carers at three to five measurement
points depending on randomisation and sub-protocol. Qualitative interviews are conducted with referring and
non-referring health care professionals (malignant disease protocol only). The primary outcome measure is ‘patient
distress due to breathlessness’ measured on a numerical rating scale (0-10). The trial includes economic evaluation.
Analysis will be on an intention to treat basis.
Discussion: This is the first evaluation of a breathlessness intervention for advanced disease to have followed the
MRC framework and one of the first palliative care trials to use fast track methodology and single-blinding. The
results will provide evidence of the clinical and cost-effectiveness of the service, informing its longer term
development and implementation of the model in other centres nationally and internationally. It adds to
methodological developments in palliative care research where complex interventions are common but evidence
sparse.
Trial Registration: ClinicalTrials.gov: NCT00678405
ISRCTN: ISRCTN04119516
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Intractable breathlessness can completely dominate a
patient’s life causing physical disability, loss of indepen-
dence and dignity and lowered self-esteem [1-3]. It is com-
mon in advanced disease, both malignant and non-
malignant. In chronic obstructive pulmonary disease
(COPD) and heart failure it is nearly universal by the time
of death, its prevalence reaching over 50% in both condi-
tions in the advanced stages. It occurs in 49% of the gen-
eral population with all cancers [4], and in 90% of those
with lung cancer [5]; these figures will rise as deaths from
mesothelioma peak in 2016 [6]. The incidence of breath-
lessness in cancer is second only to that of pain [7].
Breathlessness is also a devastating accompaniment in less
common cardio-respiratory diseases, e.g. interstitial lung
disease and cystic fibrosis. Despite its prevalence breath-
lessness remains a poorly controlled symptom in which
traditional pharmacological interventions are frequently
ineffective [1,8,9].
However, patterns of breathlessness in cancer and
COPD differ. Once patients with cancer become breath-
less they usually have a very short time to live and may
become breathless at rest, whereas patients with COPD
may live with gradually worsening symptoms and
increasingly devastating consequences for years. As a
result, patients with different diagnoses and their carers
may have different needs [10]. The effects on the patient
and family with malignant or non-malignant disease
include increased social isolation, reduced activity,
chronic anxiety, loss of employment and other changes
in roles and perceived status [3,11]. Further, the eco-
nomic burden to the healthcare system is significant [12].
Advances in the palliation of breathlessness include non-
pharmacological intervention services to reduce or contain
the severity of the sensation and, for patients with COPD,
pulmonary rehabilitation programmes [13,14]. Non phar-
macological methods for the management of breathless-
ness acknowledge the cognitive and emotional component
[9]. Breathlessness services developed for patients with
lung cancer have been formally evaluated with positive
outcomes in terms of distress due to breathlessness, func-
tioning and quality of life [15-17] however each of these
studies had limitations: all were clinic based (patients were
not seen at home); two were randomised controlled trials
but one lacked published power calculations; and the out-
comes reported by all were limited to patient outcomes i.e.
none reported staff satisfaction, the views of referrers, or
carer outcomes. Breathlessness studies have identified sig-
nificant suffering among carers who report severe anxiety
and helplessness as they witness their partners’ suffering
and feel powerless to reduce it [3].
In November 2003, a pilot Breathlessness Intervention
Service (BIS) was set up at Addenbrooke’sH o s p i t a l
consisting of a clinical specialist physiotherapist and pal-
liative care consultant [18]. BIS aims to manage the
symptom of breathlessness in patients with any disease
(malignant or non-malignant), using a rehabilitative
approach. It uses a ‘toolkit’ of interventions including:
evidence-based non-pharmacological interventions (psy-
chological, social and physical); palliative care input (e.g.
end of life issues, psychosocial issues, family concerns);
and pharmacological review. Thus BIS seeks to enhance
the self-management of breathlessness. Uniquely, care is
located flexibly in clinic or in patients’ own homes, as
appropriate. Referrals come from medical specialists, GPs
and allied health professionals (with medical consent).
From the outset its development and evaluation was
grounded in the MRC’s framework for the development
and evaluation of complex interventions [19]. Following
the developmental work conducted over the past twelve
years (Pre-clinical-Phase II [3,10,18,20,21]), BIS is now
undergoing evaluation in a Phase III definitive randomised
controlled trial (RCT). This paper presents the Phase III
RCT protocol.
The aim of Phase III is to address the following
research questions:
1. Is BIS more effective than standard care for
patients with intractable breathlessness from
advanced malignant or non-malignant disease?
2. Does it reduce patient and carer distress due to
breathlessness, and increase patients’ sense of mas-
tery of the symptom?
3. What are the experiences and views of those who
use BIS, their informal carers and the clinicians who
refer to it?
4. Is BIS cost-effective?
Methods/Design
Design
Phase III is a mixed method pragmatic fast track single
blinded randomised controlled trial of BIS versus standard
care.
BIS offers care and support to patients with malignant or
non-malignant conditions. Due to the differing disease tra-
jectories of these two groups, BIS uses two broad service
models: one for patients with malignancies (intervention
over a two week period) and one for patients with non-
malignant conditions (intervention over a four week per-
iod), summarised in Table 1. The trial therefore consists of
two sub-protocols: one for patients with malignancies (four
week protocol) and one for patients with non-malignant
conditions (eight week protocol) (Figures 1 and 2).
B a s e do nm e t h o d sp i l o t e da tP h a s eI I[ 2 0 , 2 1 ] ,c o n -
sented patients are randomised either to a ‘fast-track’
group where they receive BIS immediately or to a waiting
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Page 2 of 11Table 1 Service model for the Breathlessness Intervention Service (BIS) at Addenbrooke’s Hospital, Cambridge
University Hospitals NHS Foundation Trust (March 2008)
Disease group course: Non-malignant (nm) course Malignant (m) course
Examples: e.g. COPD, heart failure, neurological disorders e.g. all cancers, UIP
Referral: Post, fax, electronic Post, fax, electronic
Assessment lead: Clinical Specialist Physiotherapist or Clinical Specialist
Occupational Therapist
Medical Consultant (i.e. sees a doctor earlier in the
intervention than non-malignant patients)
BIS team: Clinical Specialist Occupational Therapist
Clinical Specialist Physiotherapist
Medical Consultant
Medical Consultant
Clinical Specialist Occupational Therapist
Clinical Specialist Physiotherapist
Medical assessment: May be required Always required (review of pharmacological management
at 1
st visit)
First appointment: Maximum wait of 3 weeks for first appointment Maximum wait of 1 week for first appointment
Range of face-to-face visits: 2-3 1
(with primary care professional)
Average no. of telephone
contacts (with patient/
primary care staff):
32
Ratio of face-to-face to
telephone:
1:1 2:1
Average length of service
contact:
4 weeks
+ 16 week follow up (from 1
st assessment) post any
pulmonary rehab/other referral
2 weeks
+ 6 week follow up (from 1
st assessment) post any
pulmonary rehab/other referral
Service outcome measures
collected at first
assessment:
￿ modified BORG at rest, self-reported, on exertion and on
completion of exercise test
￿ anxiety due to breathlessness at rest, self reported, on
exertion and on completion of exercise test
￿ physiological measures e.g. oxygen saturation, heart rate
￿ modified BORG at rest, self-reported, on exertion and on
completion of exercise test
￿ anxiety due to breathlessness at rest, self reported, on
exertion and on completion of exercise test (if acceptable)
￿ physiological measures e.g. oxygen saturation, heart rate
Non-pharmacological
interventions:
1
st stage of intervention More likely to be concurrent with pharmacological
interventions
Pharmacological
interventions:
2
nd stage of intervention More likely to be concurrent with non-pharmacological
interventions
1
st stage interventions
(selection & application as
clinically indicated):
The majority of these interventions are used with this
group, & taught over a longer period of time:
® explanation & reassurance
® anxiety management
® psychological support
® hand-held fan
® information fact sheets
® emergency plan
® positioning to reduce work of breathing (rest, recovery
& activity)
® breathing control
® education to patient, carer & health care generalists
® pacing & lifestyle adjustment
® individualised exercise plan
® relaxation & visualisation
® airway clearance techniques
® advice regarding nutrition & hydration
® support to family & patient to utilise education & self-
support programmes
® sleep hygiene
® smoking cessation prompt
® brief cognitive therapy
® pharmacological review
® well-being intervention
® hypnosis
® mindfulness CD
® referral to specialist services (see below)
More selective use & application of these interventions, &
taught over a shorter period of time:
® explanation & reassurance
® anxiety management
® psychological support
® hand-held fan
® information fact sheets
® emergency plan
® positioning to reduce work of breathing (rest, recovery
& activity)
® breathing control
® education to patient, carer & health care generalists
® pacing & lifestyle adjustment
® individualised exercise plan
® relaxation & visualisation
® airway clearance techniques
® advice regarding nutrition & hydration
® support to family & patient to utilise education & self-
support programmes
® sleep hygiene
® brief cognitive therapy
® pharmacological review
® well-being intervention
® hypnosis
® mindfulness CD
® referral to specialist services (see below)
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Page 3 of 11list group (control condition) where they receive the
intervention after a defined period on a waiting list dur-
ing which time they receive standard care. The advantage
of a fast-track design is that it has the strength of a RCT,
but with greater acceptability as all patients receive the
intervention. Due to the palliative status of the patients
referred to BIS, and the existence of BIS prior to this pro-
posed RCT, a traditional intervention and control group
design (where the control group would be denied access
to the service) would be unethical and unacceptable [22].
This alternative fast-track design proved highly accepta-
ble at Phase II [20].
Setting
BIS is a secondary care service which provides care in a
community setting, predominantly seeing patients in
their own homes. It principally takes referrals from the
Addenbrooke’s catchment area seeing patients from
Cambridgeshire, Hertfordshire and Essex and, where
practical, further afield.
Intervention
Table 1 outlines the minimum core interventions deliv-
ered by BIS. The service provides a thorough psycholo-
gical and physical assessment taking into account
patient and carer needs and breathlessness triggers. A
treatment plan is agreed and implemented incorporating
a range of evidence-based non-pharmacological and
pharmacological techniques relevant to the patient and
their lifestyle, helping them to self-manage their symp-
toms. A personal emergency plan is agreed and prac-
tised, with each patient receiving a copy. Paper copies of
quality controlled information leaflets are provided (also
accessible via the internet).
Standard care
For the purposes of this trial, ‘standard care’ is defined
as specialist outpatient appointments in secondary care
(e.g. respiratory, cardiology, neurology or oncology)
which may include specialist nurse input, and primary
care services.
Sample
The clinical team screen all referrals to the service against
the study inclusion and exclusion criteria (Table 2) and a
screening log is maintained.
Recruitment
A Patient Information Sheet is sent by first class post to
eligible patients inviting participation in the trial. On
the sub-protocol for patients with non-malignant condi-
tions a second mailing is sent if there is no response
Table 1 Service model for the Breathlessness Intervention Service (BIS) at Addenbrooke?’?s Hospital, Cambridge Uni-
versity Hospitals NHS Foundation Trust (March 2008) (Continued)
2
nd stage interventions: Choice of 2
nd stage interventions dependent on outcome
of first stage interventions:
® further pharmacological review e.g. low dose opioids,
anti-depressants, anxiolytics
® referral to specialist services (see below)
® referral for LTOT or SBOT assessment
2
nd stage interventions likely to be applied concurrently
with 1
st stage interventions:
®further pharmacological review e.g. low dose opioids,
anti-depressants, anxiolytics
®referral to specialist services (see below)
®referral for LTOT or SBOT assessment
Other symptom
management:
May be required Frequently required
Documentation: ® individualised patient plan
® summary to patient of outpatient consultation with
medical consultant
® discharge summary to referrer with copies to GP,
specialist services the patient was already in contact with
(e.g. respiratory physicians), other involved health care
professionals (e.g. district nurses, nursing home care staff)
® individualised patient plan
® summary to patient of outpatient consultation with
medical consultant
®discharge summary to referrer with copies to GP,
specialist services the patient was already in contact with
(e.g. respiratory physicians), other involved health care
professionals (e.g. district nurses, nursing home care staff)
® supplementary medical letters more common
Referrals: ® Pulmonary rehabilitation
® Specialist dietetic
® Specialist psychological services
® Hospice day services
® other specialist assessment
® Cardiac rehabilitation
® other rehab services
(n.b. these services usually have a wait time)
® Palliative care specialist service (n.b. rapid access
available)
® Specialist psychological services
® Hospice day services
® other specialist assessment
LTOT = long term oxygen therapy.
SBOT = short burst oxygen therapy.
While understanding that it is not possible or desirable to standardize all aspects of the Breathlessness Intervention Service (BIS) for individual patients, we have
established a service model with a minimum set of core interventions. The norm is for consultations to occur in the patient’s own home (with clinically reasoned
variance).
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Page 4 of 11within a week. On the sub-protocol for patients with
malignancies a BIS clinician conducts a telephone fol-
low-up if there is no response within a week; this clari-
fies that the patient has received a recruitment pack and
establishes whether or not they would like to participate
in the trial. If the patient (from either sub-protocol)
refuses trial participation, or there is still no response,
the service arranges to see the patient in the usual way
and they are not recruited to the trial. If the patient
responds positively to a recruitment letter a researcher
WEEK
1
2
3
4
5
6
7
8
9
10
Baseline interview t1
Withdrawn by researcher 
(significant deterioration 
between agreeing to 
recruitment visit and 
visit)
Eligible patients 
Starts to receive BIS 
Mid-intervention interview t2
End of intervention interview t3 
Mid-waiting interview t2
End of waiting interview t3 
Waiting list group starts to receive 
BIS 
Mid-intervention interview t4
End of intervention interview t5 
Taken off 
study (died) 
Fast track group
Agreed to recruitment 
visit
Waiting list group
Referrer interview
Follow up interview t5
Receives standard care
Referrer interview
= intervention
Figure 1 BIS Phase III measurement point flow chart for non-malignant conditions. shaded area = intervention.
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Page 5 of 11contacts them to arrange to visit and explain the study
in more detail, answer any questions, obtain informed
consent, conduct the baseline interview (t1) and identify
their lay carer.
If their lay carer is present at the patient’s t1 then they
are directly invited to participate in the study. If they are
willing then the researcher answers any questions,
obtains informed consent and conducts the carer baseline
interview (t1). Where possible, carers are interviewed
separately from patients as this was found to be impor-
tant in the Phase I of the evaluation [3]. If the lay carer is
not present then a recruitment pack (similar to that for
WEEK
1
2
3
4
5
6
Baseline interview t1 
Withdrawn by researcher 
(significant deterioration 
between agreeing to 
recruitment visit and 
visit) 
Eligible patients 
Starts to receive BIS 
End of intervention interview t3  End of waiting interview t3 
Waiting list group starts to receive 
BIS 
End of intervention interview t5 
Taken off 
study (died) 
Fast track group
Agreed to recruitment 
visit 
Waiting list group
Referrer interview & non-
referring health care professional
interview
Receives standard care
Follow up interview t5
Referrer & non-referring health 
care professional interview
= intervention
Figure 2 BIS Phase III measurement point flow chart - malignant conditions. shaded area = intervention.
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Page 6 of 11the patient) is either left for them with the patient, or
posted to them, depending on circumstances. They are
then approached in the same way as for patients.
Randomisation
Randomisation is carried out within 24 hours of the base-
line interview (t1) by a third party (Addenbrooke’s clinical
trials’ team) sequentially opening sealed opaque envelopes
containing the random group allocation previously gener-
ated using a computer programme by the study statistician
(University of Cambridge). The envelopes were set up by
an administrator at University of Cambridge. Patients are
allocated to the fast track group or waiting list group with
an equal 1:1 allocation ratio using the method of stratified
randomisation, with disease group (malignant, non-malig-
nant) as the single stratifier.
Patients are informed of the outcome of randomisation
by the clinical trials’ team, by telephone. BIS is then noti-
fied of the outcome of randomisation by the clinical
trials’ team (by secure email) in order that the service can
book the first appointment with the patient in-line with
the study protocols. The researcher is then notified that
randomisation has occurred, and that the patient and ser-
vice have been informed, but not the outcome of the ran-
domisation. The purpose and need for single blinding is
explained to patients and carers at the recruitment visit
and they are reminded at the start of each subsequent
blinded interview to try not to let the researcher know
their group allocation. In addition, all data are handled
using study identity numbers; group allocation identifiers
will only be added at the analysis stage. A detailed
description and discussion of single-blinding, piloted at
Phase II, has been given elsewhere [20].
Data collection interviews
Face to face mixed method interviews are conducted at
at i m ea n dp l a c ec o n v e n i e n tt o the participant (usually
their home). Careful attention is paid to both patient
and carer need, in terms of fatigue. With permission,
interviews are audio-recorded for transcription. Field
notes are recorded after each interview. Interviews are
conducted by one of three researchers: an experienced
palliative care researcher (nursing background) or one
of two sequentially employed researchers (nursing and
psychology backgrounds respectively) who have been
given full training (external in-depth interviewing
course, internal training with the interview schedule and
ongoing supervision). The researchers are allocated case-
loads so that the same researcher conducts all interviews
for patient X, their carer, their referrer and their non-
referring health care professional.
Measurement points
The data collection points (interviews) are outlined in
Figures 1 and 2. Baseline interviews are collected for all
respondents, regardless of diagnostic group, at t1, prior
to randomisation.
For patients with non-malignant conditions and their
carers, t2 occurs two weeks post t1 and the commence-
ment of BIS (fast track group) or the entering of the
waiting list (waiting list group), and t3 occurs four
weeks post commencing BIS (fast track group) or the
entering of the waiting list (waiting list group). The
waiting list group have a t4 interview scheduled two
weeks post their commencement of BIS (six weeks from
t1). T5 occurs eight weeks after t1 (i.e. on discharge
from BIS for the waiting list group or four weeks from
discharge for fast track group). This model was success-
fully piloted at Phase II [20]. Therefore for those rando-
mised to the fast track group, t2 and t3 represent mid-
point and completion of the BIS intervention, for com-
parison with these same time-points in the contempora-
neous control condition for those randomised to the
waiting list group.
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria:
Patients: Patients/Carers:
(i) appropriate referral to BIS (i) unable to give informed consent;
(ii) aged 18 years+ (ii) previously used BIS;
(iii) any patient not meeting any exclusion criteria (iii) demented/confused;
(iv) learning difficulties;
(vi) other vulnerable groups e.g. head injury, severe trauma,
mental illness;
(vii) not meeting all inclusion criteria.
Carer:
(i) informal carers (significant others, relatives, friends or neighbours) of Phase III
RCT recruits
(ii) aged 18 years+
(iii) any carer not meeting any exclusion criteria.
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Page 7 of 11Due to the shorter time frame of the service model for
patients with malignancies, there are no t2 or t4 inter-
views for patients or their carers in this group. Instead,
t3 is conducted 2 weeks post t1 i.e. on discharge from
BIS for the fast track group or just prior to commence-
ment of BIS for the waiting list group. T5 then occurs
four weeks after t1 (i.e. on discharge from BIS for the
waiting list group or two weeks from discharge for fast
track group). Therefore t3 is the time-point marking
completion of the BIS intervention for those randomised
to the fast track group, and the control condition in
those randomised to the waiting list group.
Sample size
Sample size was calculated using a power calculation,
with the potential effect size and standard deviation
informed by the existing literature and our Phase II trial
[20]. The estimated standard deviation of the primary
outcome measure is 2.5. In order to detect a 2-point dif-
ference in mean outcome between groups (equivalent to
0.8 sd effect size) with 80% power using a two-sided t-
test at the 5% level of significance, it is necessary to ana-
lyse 26 patients per arm per disease group (trial) followed
up with a primary outcome (total 104 patients).
Therefore we propose to recruit a minimum of 120
patients, 60 per disease group, to ensure adequate power,
effect size and allowance for attrition. Additionally, an
adjustment for baseline in the analysis will improve the
precision of the estimated intervention effect.
Outcome measures
Table 3 outlines the baseline and outcome measures
selected following a review of the literature and, to
avoid duplication, a review of measures used by the clin-
ical service [23-31]. Baseline characteristics and out-
comes include patients’ breathlessness, patient and carer
distress due to breathlessness, patient and carer quality
of life, patient and carer anxiety, other service use, care-
giver burden, and patient and carer expectations of and
satisfaction with BIS. The primary outcome measure is
‘distress due to breathlessness’ measured using a
Numerical Rating Scale (NRS; 0-10).
At t1, prior to quantitative data collection, a brief qua-
litative interview is conducted to identify respondents’
experiences of breathlessness, or caring for someone
who is breathless, and their expectations of BIS. Follow-
ing receipt of BIS (t3 for fast track group; t4 and t5 for
waiting list group) and after quantitative data collection,
Table 3 Patient and carer baseline and outcome measures for BIS Phase III RCT
Baseline characteristic/outcome Instrument/measure
PATIENT
Patient breathlessness Numerical Rating Scale (NRS) for breathlessness [23] at worst/average over last 24 hours/
now; modified Borg [24] at rest and on exertion & identification of activity that makes
breathlessness worst
Patient distress due to breathlessness
(primary outcome measure)
NRS for distress due to breathlessness (after Corner et al 1995 [25])
Patient quality of life Chronic Respiratory Questionnaire [26]
EQ-5D [27]
Patient anxiety & depression Hospital Anxiety and Depression Scale [28]
Patient use of other services CSRI [29]
Patient social functioning No. of times patient goes out of the house (weekly average since last interview)
Patient experience of breathlessness & expectations of
BIS/satisfaction & outcome of BIS
Brief qualitative interview:
t1 - experience of breathlessness & expectations of BIS
t3/t5 - satisfaction and outcome of BIS
CARER
Carer’s assessment of patient’s breathlessness Numerical Rating Scale (NRS) for breathlessness [23] at worst/average over last 24 hours/
now; modified Borg [24] at rest and on exertion & identification of activity that makes
breathlessness worst
Carer distress due to patient’s breathlessness NRS adapted for carer for distress to carer due to patient’s breathlessness
Carer quality of life EQ-5D [27]
Carer anxiety & depression Hospital Anxiety and Depression Scale [28]
Carer’s social functioning No. of times carer goes out of the house (weekly average since last interview)
Caregiver burden Burden Interview [30]
Caregiver Appraisal Scale [31]
Carer experience of breathlessness & expectations of BIS/
satisfaction & outcome of BIS
Brief qualitative interview:
t1 - experience of breathlessness & expectations of BIS
t3/t5 - satisfaction and outcome of BIS
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respondents’ experiences of and satisfaction with BIS.
The resulting interview schedule is therefore both quan-
titative and qualitative at each measurement point
except t2.
In addition, brief semi-structured interviews are con-
ducted with patients’ referrers two weeks after the refer-
rer’s first patient is discharged from BIS. This allows time
for receipt of discharge documentation. Referrers are
only approached for interview after their first referral to
the service within the RCT; they are assured that they
will not be asked for interview after every referral.
For patients with malignant conditions, a second health
care professional interview is sought with a non-referring
health care professional (identified by the clinical team)
to capture potential knock-on effects (positive or nega-
tive) of a BIS referral on other health care professionals.
Analysis
The same methods will be used to address the two
research questions concerning the effectiveness of BIS and
patient and carer distress and patient mastery of symp-
toms. Analyses will be presented separately for non-malig-
nant and malignant participant groups. The baseline
comparability of the arms will be examined by presenting
pre-randomisation means and proportions of patient char-
acteristics at timepoint t1 by randomised arm. The
research questions will be addressed by cross-sectional
comparison at t3 (end of intervention in fast track arm ver-
sus control condition in waiting list arm), using analysis of
covariance adjusting for the baseline of the outcome within
a linear regression framework. For the non-malignant
group, this will be supported with the same analysis at t2.
Analyses will be primarily on an intention to treat
basis. Secondary sensitivity analyses will be performed if
there are deviations to the intervention protocol (requir-
ing per protocol analysis) or there are baseline imbal-
ances (requiring analysis adjustment). A graph will
summarise the mean response over the time-points, with
estimates and 95% confidence intervals for differences
both between arms and within each arm over time from
t3 to t5 (using paired t-tests). If a chi-squared test does
not indicate that the t3 randomised effects are dissimilar
in malignant and non-malignant groups, a simple average
combined effect will be estimated with a narrower overall
confidence interval to inform Phase IV. All analyses will
be two-sided and assessed at the 5% significance level
using SPSS software.
Qualitative data will be transcribed by an independent
transcription company, checked and anonymised before
analysis; transcripts will then be imported into NVivo
software to facilitate the conduct of framework analysis
[32]. Mixed method analyses will purposively sample
qualitative data, based on quantitative findings.
Cost-effectiveness
The cost of services used by each patient will be calcu-
lated from service activity data and appropriate unit
costs. The BIS intervention costs will be based on staff
salary costs, plus oncosts, overheads and equipment and
divided by a relevant level of activity. Information on the
use of other health and social services and informal care
(proxy-valued as a homecare worker) will be collected
with the Client Service Receipt Inventory (CSRI) [29].
This will be combined with appropriate unit cost data
[e.g. [33]] to generate service costs. Cost comparisons
will be made using bootstrapping methods to account for
any skewness in data distribution. Cost-effectiveness will
be assessed by combining cost data with that on the pri-
mary outcome measure (distress due to breathlessness)
and quality-adjusted life years (QALYs), in the form of
incremental cost-effectiveness ratios (if the intervention
group has better outcomes and higher costs) and cost-
effectiveness acceptability curves which will show the
probability that the intervention is cost-effective for a
range a values placed on a unit improvement in outcome
compared to the waiting list control group.
Monitoring
A Trial Management Group consisting of the clinical
(BIS) and research teams (MF, JG/BBK) manage the
everyday conduct of the trial through monthly face-to-
face meetings and interim secure email contact. A Trial
Advisory Group meets six monthly and consist of the
clinical and research teams, the trial economist and sta-
tistician, academics (with expertise in complex interven-
tions and palliative care RCTs), respiratory and
oncology specialists, NHS managers, patients and carers.
Approvals and trial registration
Ethical approval was obtained from the Cambridgeshire 2
Research Ethics Committee (08/H0308/157) and R&D
approval and sponsorship from Addenbrooke’sH o s p i t a l ,
Cambridge University Hospitals NHS Foundation Trust
(A091322): current protocol version v5 110810. The trial
is registered with http://ClinicalTrials.gov (NCT00678405)
and Current Controlled Trials (ISRCTN04119516).
Discussion
This is the first evaluation of an intervention for breath-
lessness in advanced disease to have followed the MRC
framework; only recently has the framework been used
in a palliative care setting [34]. It is also one of the very
few trials in palliative care to propose the use of fast
track methodology [20,34,35], and the first, as far as we
are aware, to combine this with single-blinding (other
than our Phase II trial [20]).
The Phase III protocol described here was developed
based on our Phase II pilot trial [20]. One limitation of
Farquhar et al. Trials 2011, 12:130
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Page 9 of 11this is that the pilot focused only on patients with
COPD. The reason for this was that COPD patients
made (and continue to make) up the largest group of
patients referred to BIS and existing studies of breath-
lessness interventions had focused on patients with
malignancies. Funding was sought for a Phase II trial
with patients with malignancies but was unsuccessful.
Thus the methods outlined here for Phase III have not
been tested on patients with malignant conditions.
A further limitation of this Phase III study may be
that although some outcome measures were revised as a
result of Phase II, the new measures adopted for Phase
III were not subjected to formal piloting, nor were the
economic evaluation measures i.e. EQ-5D and CSRI.
The MRC framework has provided a useful structure
for the systematic development and evaluation of BIS
[3,10,20,21], however, as Booth [36] has commented, the
length of time for completion of the framework is con-
siderable. The development work for the Pre-Clinical
Phase began in 1998 and Phase III is due for completion
in 2012. In this time there will have been changing con-
textual factors that will need to be considered and
accounted for in terms of their impact on both the
development of the service and the outcome of its eva-
luation. Campbell et al (2007) noted that the setting in
which an intervention is given must be understood
before the intervention can be used elsewhere [37]; this
will be particularly important as the evaluation of BIS
moves into Phase IV.
The results of this Phase III trial will therefore provide
evidence of the effectiveness and cost-effectiveness of
BIS, inform the long term development of the service
and its implementation in other centres nationally and
internationally, as well as adding to methodological
developments in palliative care research and the devel-
opment and evaluation of complex interventions.
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BIS: Breathlessness Intervention Service; RCT: randomised controlled trial;
COPD: chronic obstructive pulmonary disease; MRC: Medical Research
Council; NRS: numerical rating scale; CSRI: Client Services Receipt Inventory.
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